These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33530261)

  • 41. [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
    Zhang YS; Cong WH; Zhang JJ; Guo FF; Li HM
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1263-1271. PubMed ID: 32281335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How do arbidol and its analogs inhibit the SARS-CoV-2?
    Aktas A; Tuzun B; Taskin AH; Sayin K; Ataseven H
    Bratisl Lek Listy; 2020; 121(10):705-711. PubMed ID: 32955901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. East meets West in COVID-19 therapeutics.
    Wang S; Zeng X; Wang Y; Zhao Y; Chen W; Chen YZ
    Pharmacol Res; 2020 Sep; 159():105008. PubMed ID: 32531323
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy of Ninjin'yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit.
    Aomatsu N; Shigemitsu K; Nakagawa H; Morooka T; Ishikawa J; Yamashita T; Tsuruoka A; Fuke A; Motoyama K; Kitagawa D; Ikeda K; Maeda K; Shirano M; Rinka H
    Neuropeptides; 2021 Dec; 90():102201. PubMed ID: 34753072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: A retrospective cohort study.
    Shi MY; Sun SQ; Zhang W; Zhang X; Xu GH; Chen X; Su ZJ; Song XM; Liu LJ; Zhang YB; Zhang YL; Sun M; Chen Q; Xue Y; Lü H; Yuan WA; Chen XR; Lu YF
    J Integr Med; 2021 May; 19(3):226-231. PubMed ID: 33583756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
    Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
    Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Traditional Chinese Medicine on coronavirus disease 2019 in 92 patients: a retrospective study.
    Guihua XU; Feifei C; Wei Z; Yingen WU; Xiaorong C; Kehua S; Zhenwei W; Miaoyan S; Xing Z; Yunfei LU; Weian Y; Hua L; Xuan C
    J Tradit Chin Med; 2023 Jun; 43(3):582-587. PubMed ID: 37147761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
    Xia L; Shi Y; Su J; Friedemann T; Tao Z; Lu Y; Ling Y; Lv Y; Zhao R; Geng Z; Cui X; Lu H; Schröder S
    Phytomedicine; 2021 May; 85():153390. PubMed ID: 33158717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Meta analysis on the treatment of coronavirus disease 2019 by traditional Chinese and Western medicine].
    Wang Q; Mei J; Wang C; Wu L; Gao H; Zhang H; Chen F
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Jun; 33(6):714-720. PubMed ID: 34296692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019].
    Gu M; Liu J; Shi NN; Li XD; Huang ZD; Wu JK; Wang YG; Wang YP; Zhai HQ; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1253-1258. PubMed ID: 32281333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective comparison of drugs against COVID-19.
    Tan J; Yuan Y; Xu C; Song C; Liu D; Ma D; Gao Q
    Virus Res; 2021 Mar; 294():198262. PubMed ID: 33333102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy analysis of Arbidol treatment in patients with 2019 novel coronavirus pneumonia: a retrospective cohort study.
    Chen N; Wang X; Zhang S; Lin R; Jiang Y
    Ann Palliat Med; 2021 Oct; 10(10):10626-10632. PubMed ID: 34763510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.
    Yu R; Zhang S; Zhao D; Yuan Z
    Expert Rev Mol Med; 2022 Jan; 24():e5. PubMed ID: 34986905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.
    Fan Z; Guo G; Che X; Yang Y; Liu Y; Li L; Chang X; Han L; Cai X; Tang H
    Medicine (Baltimore); 2021 May; 100(21):e26059. PubMed ID: 34032734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Corticosteroid, oseltamivir and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019.
    Hu F; Yin G; Chen Y; Song J; Ye M; Liu J; Chen C; Song Y; Tang X; Zhang Y
    Clin Respir J; 2020 Nov; 14(11):1067-1075. PubMed ID: 32750201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.